Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis Juan Escalas, PhD, MD, Nicole Knöpfel, MD, Ana Martin-Santiago,

A girl with a solitary red bulla

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis Alan Menter,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Efficacy of simvastatin in plaque psoriasis: A pilot study

Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review Nolan J. Maloney, BS, Lisa D. Hisaw,

Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States Caroline P. Schaefer,

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

David T. Pompei, Pharm D, Kameron S. Rezzadeh, BS, Kate V

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry David Fiorentino, MD, PhD, Vincent Ho, MD, Mark.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Applying for dermatology residency is difficult and expensive

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Treatment of toxic epidermal necrolysis in North America

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Characterization of disease burden, comorbidities, and treatment use in a large, US- based cohort: Results from the Corrona Psoriasis Registry Bruce Strober,

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Treatment of psoriasis vulgaris using low-dose naltrexone

Partik Singh, BA, Jonathan I. Silverberg, MD, MPH, PhD

Infectious rash after riding elephants

Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period

Robert Kantor, BS, Prarthana Dalal, BS, David Cella, PhD, Jonathan I

Lip edema Journal of the American Academy of Dermatology

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis.

Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort Elaine Kunzler, MD, Stephanie Florez-Pollack,

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Jules B. Lipoff, MD, Neha Jariwala, BS, Monica Paz, MD, Rudolf R

Guidelines of care for the management of psoriasis and psoriatic arthritis Alan Menter, MD, Neil J. Korman, MD, PhD, Craig A. Elmets, MD, Steven R. Feldman,

Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families Lucy Y. Liu,

Jennifer L. Hundley, MD, Christie L

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Etanercept therapy in two patients with psoriasis and concomitant hepatitis C Clara De Simone, MD, Andrea Paradisi, MD, Rodolfo Capizzi, MD, Angelo Carbone,

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Deficiency of sun protection advertising exists in consumer magazines across demographic groups and varies by target demographic Lauren E. Wiznia, MD,

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy Trevor Markham, MD, Ronan Mullan,

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Presentation transcript:

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]) Bruce E. Strober, MD, PhD, Robert Bissonnette, MD, David Fiorentino, MD, PhD, Alexa B. Kimball, MPH, MD, Luigi Naldi, MD, Neil H. Shear, MD, Kavitha Goyal, MD, Steven Fakharzadeh, MD, PhD, Stephen Calabro, MS, Wayne Langholff, PhD, Yin You, MS, Claudia Galindo, MD, Seina Lee, MS, PharmD, Mark G. Lebwohl, MD Journal of the American Academy of Dermatology Volume 74, Issue 5, Pages 851-861.e4 (May 2016) DOI: 10.1016/j.jaad.2015.12.017 Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Psoriasis. Proportion of patients with Physician Global Assessment (PGA) score of 0 (clear) or 1 (minimal) at 6 and 12 months; patients initiating ustekinumab, infliximab, adalimumab, or etanercept on registry. Journal of the American Academy of Dermatology 2016 74, 851-861.e4DOI: (10.1016/j.jaad.2015.12.017) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Psoriasis. Mean decrease in percentage of body surface area (%BSA) with psoriasis at 6 and 12 months; patients initiating ustekinumab, infliximab, adalimumab, or etanercept on registry. Journal of the American Academy of Dermatology 2016 74, 851-861.e4DOI: (10.1016/j.jaad.2015.12.017) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Psoriasis. Proportion of patients achieving clinically meaningful improvement in Dermatology Life Quality Index (DLQI) score (≥5) by DLQI level (<10 and ≥10) at the time of initiating ustekinumab, infliximab, adalimumab, or etanercept on registry: 6 (A) and 12 (B) months. Journal of the American Academy of Dermatology 2016 74, 851-861.e4DOI: (10.1016/j.jaad.2015.12.017) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Psoriasis. Proportions of patients achieving Dermatology Life Quality Index (DLQI) score of 0 or 1 (no impact on health-related quality of life) at baseline and at 6 and 12 months; patients initiating ustekinumab, infliximab, adalimumab, or etanercept on registry. Journal of the American Academy of Dermatology 2016 74, 851-861.e4DOI: (10.1016/j.jaad.2015.12.017) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions